Figure 2.
(a) Ex vivo distribution of 68Ga-NODAGA-indole and 68Ga-NODAGA-carboline 2 h post injection, expressed as percent injected dose per gram of tissue (%ID/g) (mean ± SE) in various organs. (b) Ex-vivo uptake of 68Ga-NODAGA-indole and 68Ga-NODAGA-carboline in lungs from sham- (n=10) and bleomycin-treated (n=14) mice 2 h post injection, expressed as %ID/lung. The uptake of 68Ga-NODAGA-indole in fibrotic lungs is 7-fold higher than in sham animals and 7- or 8-fold higher than the lung uptake of 68Ga-NODAGA-carboline in bleomycin- or sham-treated mice, respectively. (c) Strong correlation (R2=0.98, p < 0.0001) between lung uptake of 68Ga-NODAGA-indole and allysine content in sham- (n=6) and bleomycin-treated (n=8) mice, (one outlier is highlighted in red, which was not included in the linear regression analysis). Data in 2a and 2b were analyzed with one-way ANOVA, followed by post-hoc Tukey tests; * p < 0.05, ** p < 0.01, *** p < 0.001.